Cancer Pharmacokinetics and Pharmacodynamics Facility

翻译后摘要：癌症药代动力学和药效学设施（CPPF） 希尔曼癌症中心（HCC）癌症药代动力学和药效学机构（CPPF）是一家 重要的共享资源，支持由HCC研究计划进行的科学，并有一个主要 通过提供最先进和全面的技术， 为临床前和临床癌症治疗研究提供定量和定性生物分析支持。的 CPPF的活动因其在制定和提供 研究药物的PK和PD分析。 CPPF：（1）通过协助PK和PD研究设计，为研究者提供广泛的药理学专业知识 （2）开发和提供质量保证/质量控制的定量和定性 用于快速有效的PK和PD生物分析的分析能力;以及（3）通过以下方式整合PK/PD数据： 复杂的数据分析。 CPPF位于两个相邻的实验室空间，在HCC研究馆有一个共享的办公室。主要 设备包括3台Waters沃茨QuattroMicro LC-MS/MS、2台SCIEX 4000 LC-MS/MS（1台混合线性离子阱）、2台 HPLC-UV/FL/DAD，1台HPLC-UV/RAD，1台原子吸收光谱仪，LICOR Odyssey红外扫描仪， Tecan Infinite酶标仪和Nexcelom Cellometer K2细胞计数器。辅助设备包括 -20 °C和-80 °C冷冻箱、氮气发生器和不间断电源，以及 包括液体闪烁计数器的共享仪器。 CPPF由药物科学和医学教授Jan Beumer博士和John Schmitz，医学副教授，并由HCC咨询委员会监督， HCC成员。Beumer博士领导和Schmitz博士积极参与每周梅里尔Egorin 转化研究会议，其中HCC早期药物开发项目由一个跨 由基础、转化和临床科学家组成的学科小组，从而确保适当的考虑 CPPF在这些项目中的作用。 在此资助期间，CPPF分析了总共36名独特研究者的样本，并提供了 支持所有7个HCC研究项目。在此资助期间，CPPF开发了37种新的检测方法， 平均每年使用22次检测，分析了30，000多个样本（不包括 校准品、质控品或测定验证样品）。伙伴关系基金支助了30项同行审查赠款和70项 出版物，其中30篇专注于临床试验，19篇专注于开发新的 测定方法学。

Abstract: Cancer Pharmacokinetics and Pharmacodynamics Facility (CPPF) The Hillman Cancer Center (HCC) Cancer Pharmacokinetics and Pharmacodynamics Facility (CPPF) is an important shared resource that supports science conducted by the HCC research programs and has a major impact on cancer drug development on a national level by providing state-of-the-art and comprehensive quantitative and qualitative bioanalytical support for preclinical and clinical cancer therapeutic studies. The activities of CPPF have earned national recognition for its exceptional service in developing and delivering PK and PD analyses of investigational agents. CPPF: (1) provides extensive pharmacology expertise to investigators by assisting in PK and PD study design and sample collection; (2) develops and provides quality-assured/quality-controlled quantitative and qualitative assay capabilities for rapid and efficient PK and PD bioanalyses; and (3) integrates PK/PD data through sophisticated data analyses. CPPF is located in two contiguous lab spaces with a shared office pod in the HCC Research Pavilion. Major equipment includes 3 Waters QuattroMicro LC-MS/MS, 2 SCIEX4000 LC-MS/MS (1 hybrid linear ion-trap), 2 HPLC-UV/FL/DAD, 1 HPLC-UV/RAD, 1 atomic absorption spectrometer, a LICOR Odyssey infra-red scanner, a Tecan Infinite Microplate Reader, and a Nexcelom Cellometer K2 Cell counter. Ancillary equipment includes -20 °C and -80 °C freezers, a nitrogen generator, and an uninterrupted power supply, as well as access to shared instrumentations including a liquid scintillation counter. CPPF is directed by Drs. Jan Beumer, Professor of Pharmaceutical Sciences and Medicine, and John Schmitz, Associate Professor of Medicine, and is overseen by an HCC Advisory Committee made up of HCC members. Dr. Beumer leads and Dr. Schmitz actively participates in the weekly Merrill Egorin Translational Research meeting, where HCC early drug development projects are discussed by an inter- disciplinary group of basic, translational, and clinical scientists, thereby ensuring appropriate consideration of CPPF’s role in these projects. During this funding period, CPPF analyzed samples for a total of 36 unique investigators and provided support for all 7 HCC research programs. During this funding period, CPPF developed 37 new assays, an average of 22 assays were used per year, and more than 30,000 samples were analyzed (excluding calibrators, quality controls or assay validation samples). CPPF supported 30 peer-reviewed grants and 70 publications, 30 of which were focused on clinical trials, and 19 of which focused on development of novel assay methodologies.